News
ENTA
12.96
+0.93%
0.12
Weekly Report: what happened at ENTA last week (0921-0925)?
Weekly Report · 5d ago
Enanta Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 09/23 10:55
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
Benzinga · 09/23 10:45
H.C. Wainwright Remains a Buy on Enanta Pharmaceuticals (ENTA)
TipRanks · 09/22 09:45
Weekly Report: what happened at ENTA last week (0914-0918)?
Weekly Report · 09/21 09:38
Weekly Report: what happened at ENTA last week (0907-0911)?
Weekly Report · 09/14 09:40
Weekly Report: what happened at ENTA last week (0831-0904)?
Weekly Report · 09/07 09:37
Enanta Pharmaceuticals to Participate in September Investor Conferences
Barchart · 09/01 06:00
Weekly Report: what happened at ENTA last week (0824-0828)?
Weekly Report · 08/31 09:41
Weekly Report: what happened at ENTA last week (0817-0821)?
Weekly Report · 08/24 09:41
Weekly Report: what happened at ENTA last week (0810-0814)?
Weekly Report · 08/17 09:42
Enanta Pharmaceuticals Flags Ongoing Uncertainty as 2025 Risk Factors Continue to Shape 2026 Outlook
TipRanks · 08/13 06:01
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses
Simply Wall St · 08/11 23:46
H.C. Wainwright Sticks to Their Buy Rating for Enanta Pharmaceuticals (ENTA)
TipRanks · 08/11 15:55
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 08/10 21:10
*Enanta Pharmaceuticals: Cash Runway Expected to Fund Ops Into Fiscal 2029 >ENTA
Dow Jones · 08/10 20:12
*Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA
Dow Jones · 08/10 20:11
Enanta Pharma GAAP EPS of -$0.67 misses by $0.16, revenue of $14.35M misses by $2.47M
Seeking Alpha · 08/10 20:07
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Benzinga · 08/10 20:05
Enanta reports Q3 EPS (67c), consensus (51c)
TipRanks · 08/10 20:05
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.